Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPAK: MRI and PET Imaging for Pembrolizumab Response in Melanoma
NCT02591654Phase 1Terminated
- Sponsor
- Columbia University
- Start
- Oct 2015
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in melanoma, sponsored by Columbia University. Primary endpoint: Prevalence of lesion detection (sensitivity). Started Oct 2015; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02591654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591654.